DexCom has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are up 106.11% year to date as of the close of trading on Thursday. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, 2 analysts rate it a sell, and 3 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE TheStreet Quant Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.